NCT07569887 Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment
| NCT ID | NCT07569887 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Unruptured Brain Arteriovenous Malformation |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-06-16 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-06-16 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the clinical trial is to describe perfusion and metabolic alterations in different brain regions before and six months after surgical treatment of arteriovenous malformations in adult patients with unruptured arteriovenous malformations.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 and older * Admitted for an unruptured arteriovenous malformation with a decision to proceed with surgery Exclusion Criteria: * Patients who refuse surgical treatment for arteriovenous malformation * Contraindications to 18F-FDG PET (uncontrolled diabete) * Patients' inability to lie still for 40 minutes * Patients with a confirmed diagnosis of neurodegenerative or psychiatric disorders * Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code) * Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code) * Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code) * Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code) * Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code) * Failure to obtain written informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07569887 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Unruptured Brain Arteriovenous Malformation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07569887 currently recruiting?
Yes, NCT07569887 is actively recruiting participants. Contact the research team at l-ribeiro@chu-montpellier.fr for enrollment information.
Where is the NCT07569887 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT07569887 clinical trial?
NCT07569887 is sponsored by University Hospital, Montpellier. The trial plans to enroll 10 participants.